Loading...
Market
What will be the next significant milestone for the PfSPZ Vaccine in pre-pregnancy malaria prevention by end of 2024?
2
Resolution / Starting Odds
Phase 3 trial initiation • 25%
WHO approval • 25%
Inclusion in national programs • 25%
No significant milestone • 25%
Official announcements from NIAID or peer-reviewed publications
Story
Pre-Pregnancy Malaria Vaccine Shows Promise in Mali Trials
Aug 15, 2024, 06:26 AM
Recent findings from a trial conducted in Mali indicate that a pre-pregnancy malaria vaccine, known as the PfSPZ Vaccine, could significantly protect women and their babies from malaria. The research, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), involved two randomized, double-blind, placebo-controlled phase 1 and 2 trials. Scientists have hailed the results as a 'tremendous advance' in preventing the deadly parasitic disease in pregnant women. The trial's success could pave the way for improved malaria prevention strategies for women anticipating pregnancy.
View original story
Similar markets
Phase 3 trial initiation • 25%
FDA Breakthrough Therapy designation • 25%
Partnership announcement • 25%
No major milestone • 25%
Approval for public use • 25%
Widespread distribution • 25%
Inclusion in national vaccination programs • 25%
None of the above • 25%
Insecticide-treated nets • 25%
Antimalarial drugs • 25%
Indoor residual spraying • 25%
Vaccine deployment • 25%
Yes • 50%
No • 50%
Dose escalation • 25%
Safety assessment • 25%
Efficacy assessment • 25%
Trial termination • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Kenya • 25%
Uganda • 25%
Tanzania • 25%
Other • 25%
Revised guidelines • 25%
Increased studies • 25%
No change • 25%
Other actions • 25%
Supply chain issues • 25%
Regulatory hurdles • 25%
Vaccine hesitancy • 25%
Competition from other vaccines • 25%
Yes • 50%
No • 50%